Viliuyskiy encephalomyelitis as primary chronic neurodegenerative disorder
https://doi.org/10.25789/YMJ.2019.68.30
Abstract
The paper presents a new concept of the nature of Viliuisk encephalomyelitis – the unique disease of the Sakha ethnic group as primary chronic neurodegenerative disorder. It is based on an analysis of the participation of TNF superfamily members in the pathogenesis of the disease. The ligands and receptors of TNF superfamily are key players of important biological processes, including the maintenance of tissue cell homeostasis using immunity mechanisms. It is suggested that sTRAIL ligand induce the loss of neurons in the cases of a primary chronic degenerative process. The sTNFα ligand is associated with an inflammatory complication of this disease under conditions of stress and perhaps participates in the neuronal necrosis in the acute stage. Elevated levels of sCD40L, detected in the plasma of patients, may act as a factor of the development of microvascular pathology, the cause of chronic hypoxia, inducing and supporting chronic processes of brain tissue atrophy.
Keywords
Supporting agencies: This work was supported by the Ministry of Science and Higher Education of the Russian Federation (Project No. FSRG-2017-0016).
About the Authors
V. L. Osakovsky
Medical Institute of MK Ammosov NorthEastern Federal University
Russian Federation
Russian Federation
Osakovsky Vladimir Leonidovich – PhD, Chief Researcher, Research Center
Oiunsky Street, Yakutsk, 677000, +79248703167
T. M. Sivtseva
Medical Institute of MK Ammosov North-Eastern Federal University
Russian Federation
Russian Federation
Sivtseva Tatyana Mikhailovna – PhD, Senior Researcher, Research Center
Oiunsky Street, Yakutsk, 677000
+79142237432
References
1. Avtsyn A.P. New data on the epidemiology and morphology of Viliuisk encephalomyelitis / A.P. Avtsyn, A.A. Zhavaronkov // Pathology Archive. – 1994. – V. 56. - №4. - p.39-44.
2. Goldfarb L.G. Viliuisk encephalomyelitis / L.G. Goldfarb, V.A. Vladimirtsev, N.M. Renwick, F.A. Platonov. – Novosibirsk: Publishing house of the Siberian Branch RAS, 2014. – 242 p.
3. Vladimirtsev A.I. Clinical and epidemiological observations in foci of Vilyui encephalitis: Diss. Cand. Med. Science / A.I. Vladimirtsev. - 1985.
4. Osakovsky V.L. Immunopathology of Viliuisk encephalomyelitis / V.L. Osakovsky, T.M. Sivtseva // Neuroimmunology. – 2012. - 3-4. - P. 22-27.
5. Features of a picture of blood of patients with the Viliuisk encephalomyelitis / L.P. Sizikova, A.A. Dadaeva, E.L. Subbotina [et.al.] // Siberian Medical Journal. - 2008. - №3. - p. 47-50.
6. Petrov P.A. Viliuisk encephalitis / P.A. Petrov // Neuropathology and psychiatry. - 1958. - p. 669-674.
7. Tazlova R.S. Mental disorders in typical forms of Viliuisky encephalitis (encephalomyelitis) / R.S. Tazlova. - Irkutsk: Irkutsk University Publishing House. - 1982. - 196 p.
8. Characteristics of the pathomorphological process of the central nervous system in Viliuisk encephalomyelitis: report on the completed research work / A.P. Savinov, G.L. Zubri, I.A. Robinson. - 1973.
9. Shapoval A.N. Viliuisk encephalitis / A.N. Shapoval. – Yakutsk, 1959. - 154 p.
10. Bremer E. Targeting of the tumor necrosis factor receptor superfamily for cancer immunotherapy / E. Bremer // ISRN Oncol. – 2013. – 2013. – Article ID 371854, 25 pages. http://dx.doi.org/10.1155/2013/371854
11. CDP7657, an anti-CD40L antibody lacking an Fc domain, inhibits CD40L – dependent immune responses without thrombotic complications: an in vivo study / A. Shock, L. Burkly, I. Wakefield, [et. al.] // Arthritis Res. Ther. – 2015. – 17. – 234. doi: 10.1186/s13075-015-0757-4.
12. Crosstalk between apoptosis, necrosis and autophagy / V. Nikoletopoulou, M. Markaki, K. Palikaras, N. Tavernarakis // Biochimica et Biophisica Acta. – 2013. – 1833(12). – P. 3448-3459. doi: 10.1016/j.bbamcr.2013.06.001.
13. Elmetwali T. CD40 ligand-induced carcinoma cell death: a balance between activation of TNFR-associated factor (TRAF) 3-dependent death signals and suppression of TRAF6-dependent survival signals / T.Elmetwali, LS Young , DH Palmer // J. immunol. – 2010. - 184. - P. 1111-1120. doi: 10.4049/jimmunol.0900528.
14. Goldfarb L.G. Viliuisk encephalomyelitis in the Yakut people of Siberia / L.G. Goldfarb, D.C. Gajdusek // Brain. – 1992. – 115. – P. 961-78. doi: 10.1093/brain/115.4.961
15. Hehlgans T. The intriguing biology of the tumour necrosis factor/tumour necrosis fac tor receptor superfamily: Players, rules and the games / T. Hehlgans, K. Pfeffer // Immunology. – 2005. – 115. – P. 1-20. doi.org/10.1111/j.1365-2567.2005.02143.x
16. Human brain-cell death induced by TNF related apoptosis- induced ligand (Trail). / R. Nitsch, I. Bechmann, RA Deisz, [et.al.] // Lancet. – 2000. – 356. – P.827-82. doi.org/10.1016/S0140-6736(00)02659-3
17. Intrathecal synthesis of oligoclonal IgG in patients with Viliuisk encephalomyelitis: The relationship between oligoclonal bands and clinical features / T.M. Sivtseva, V.A. Vladimirtsev, R.S. Nikitina [et.al.] // J Neurol Sci. – 2018. – 384. – P. 84–88. DOI: https://doi.org/10.1016/j.jns.2017.11.030
18. Locksley RM. The TNF and TNF receptor superfamilies, / RM. Locksley, N. Killeenl, MJ. Leonardo // Cell. – 2001. – 104 (4). – P. 487-501. doi.org/10.1016/S0092-8674(01)00237-9.
19. Michel N.A. CD40L and Its Receptors in Atherothrombosis – An Update /N.A. Michel, A. Zirlik, D. Wolf // Front. Cardiovasc. Med. – 2017. – 4. doi:10.3389/fcvm.2017.00040.
20. Multiple minute infarcts due to occlusion of CNS perforating arteries in viliuisk encephalitis: histological resemblance to NeuroBechet disease / F. Ikuta, S. Takeda [et.al.] // Abstracts XIII International Congress of neuropathology. – Perth; Melburn, 1997.
21. Pharmacokinetics/dynamics of 5c8, a monoclonal antibody to CD154 (CD40 ligand) suppression of an immune response in monkeys / J.V. Gobburu, C. Tenhoor, M.C. Rogge [et al.] // J. Pharmacol. Exp. Ther. – 1998. – 286. – P. 925-930.
22. Platelet CD40L induces activation astrocytes and microgla in hypertension / SA. Bhat, R. Goel, R. Shukla, K. Hanif // Brain Behav. Immun. – 2016. – v.59. – P. 173-189. doi: 10.1016/j.bbi.2016.09.021.
23. Reduction of atherosclerosis in mice by inhibition of CD40 signalling / F. Mach, U. Schonbeck, G.K. Sukhova, [et al.] // Nature. – 1998. – 394. – P. 200-203.
24. Soluble CD40 ligand contributes to blood – brain barrier breakdown and central nervous system inflammation in multiple sclerosis and neuromyelitis optica spectrum disorder / H. Masuda, M. Mori, T. Uchida, [et al.] // J. Neuroimmunol. – 2017. – 305. – P. 102–107. doi:10.1016/j.jneuroim.2017.01.024.
25. Targeting the p53 pathway of apoptosis / J.D. Amaral, J.M. Xavier, C.J. Steer, C.M. Rodrigues // Curr Pharm Des. – 2010. – 16(22). – 2493-503. doi: 10.2174/138161210791959818
26. The association between impaired glucose tolerance and soluble CD40 ligand : a 15-year prospective cohort study / H. Linna, K. Suija, U.R.K. Herzig [et al.] // Aging Clin Exp. Res. – 2016. -28. - 1243–1249. doi:10.1007/s40520-015-0524-z.
27. The role of soluble CD40L in immunosuppression. / J. Schlom, C. Jochems, J.L. Gulley, J. Huang// Oncoimmunology. – 2013. - 2. - e22546. http://dx.doi.org/10.4161/onco.22546
28. The signaling role of CD40L in platelet biology and in platelet component transfusion / C. Aloui, A. Prigent, C. Sut // Int.J.Mol.Sci. – 2014. - v.15 (12). - P. 22342-22364. doi: 10.3390/ijms151222342.
29. TNF-related apoptosis-inducing ligand level in Alzheimer disease / S. Genc, MY. Egrilmez, E. Yaka, et al. // Neurol Sci. – 2009. - Jun; 30(3). – P. 263-267. doi: 10.1007/s10072-009-0047-5.
30. Tracey K.J. Reflex control of immunity // K.J. Tracey //Nat. Rev.Immunol. – 2009. - 9(6). – P. 418-428. doi: 10.1038/nri2566.
31. Trail-induced apoptosis between tumor therapy and immunopathology / N. Corazza, D. Kassahn, S. Jakob, [et al.] //Annals of the new York Academy of sciences. – 2009. – 1171. – P. 50-58. doi: 10.1111/j.1749-6632.2009.04905.x.
32. van Kooten C. CD40-CD40 ligand / C. van Kooten, J. Banchereau // J Leukoc Biol. – 2000. – 67. – P. 2–17. https://doi.org/10.1002/jlb.67.1.2
33. Viliuisk encephalomyelitis — review of the spectrum of pathological changes / C.A. McLean, C.L. Masters, V.A. Vladimirtsev, [et al.] // Neuropathol. Appl. Neurobiol. – 1997. – 23. –P. 212–217. DOI: 10.1111/j.1365-2990.1997.tb01204.x
Review
For citations:
Osakovsky V.L., Sivtseva T.M. Viliuyskiy encephalomyelitis as primary chronic neurodegenerative disorder. Yakut Medical Journal. 2019;(4):106-110. https://doi.org/10.25789/YMJ.2019.68.30
Views:
1
Email this article 